Lilly has launched a redesigned pen-injector device for administering Forteo (teriparatide [recombinant] injection) that features a larger and wider body, a no-priming injection system, and color-coded parts for patient training and communication.

Forteo is indicated for the treatment of men and postmenopausal women with osteoporosis who are at high risk for having fractures.

For more information call (866) 4FORTEO or visit www.forteo.com.